TIP25-243: Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians' choice in advance/recurrent endometrial carcinoma previously treated with anti-PD-(L)1 immunotherapy Meeting Abstract
| Authors: | Eskander, R.; Lee, J. Y.; Mirza, M.; Lorusso, D.; Mackay, H.; Ray-Coquard, I.; Oaknin, A.; Gonzalez-Martin, A.; Hasegawa, K.; Corr, B.; Wu, X.; Leary, A.; Hu, T.; Dutta, L.; Okpara, C.; McKenzie, J.; Makker, V. |
| Abstract Title: | TIP25-243: Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians' choice in advance/recurrent endometrial carcinoma previously treated with anti-PD-(L)1 immunotherapy |
| Meeting Title: | NCCN 2025 Annual Conference |
| Keywords: | aged; side effect; endometrium carcinoma; randomized controlled trial; immunotherapy; physician; optimal drug dose; drug therapy; adverse drug reaction; therapy; eribulin; drug comparison; lenvatinib; human; article |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 23 |
| Issue: | 3.5 |
| Meeting Dates: | 2025 Mar 28-30 |
| Meeting Location: | Orlando, FL |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2025-03-01 |
| Start Page: | TIP25-243 |
| Language: | English |
| DOI: | 10.6004/jnccn.2024.7252 |
| PUBMED: | 40157347 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Meeting Abstract -- Source: Scopus |
